Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 4
2008 7
2009 7
2010 7
2011 16
2012 11
2013 9
2014 21
2015 15
2016 13
2017 15
2018 10
2019 5
2020 9
2021 5
2022 11
2023 13
2024 11
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Results by year

Filters applied: . Clear all
Page 1
Machine Learning for Cerebrovascular Disorders.
Yu Y, Chen DYT. Yu Y, et al. 2023 Jul 23. In: Colliot O, editor. Machine Learning for Brain Disorders [Internet]. New York, NY: Humana; 2023. Chapter 29. 2023 Jul 23. In: Colliot O, editor. Machine Learning for Brain Disorders [Internet]. New York, NY: Humana; 2023. Chapter 29. PMID: 37988525 Free Books & Documents. Review.
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.
Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Morgan TM, et al. J Urol. 2024 Apr;211(4):518-525. doi: 10.1097/JU.0000000000003891. Epub 2024 Feb 29. J Urol. 2024. PMID: 38421243
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.
Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Morgan TM, et al. J Urol. 2024 Apr;211(4):509-517. doi: 10.1097/JU.0000000000003892. Epub 2024 Feb 29. J Urol. 2024. PMID: 38421253
A Description and Safety Overview of Irreversible Electroporation for Prostate Tissue Ablation in Intermediate-Risk Prostate Cancer Patients: Preliminary Results from the PRESERVE Trial.
George AK, Miocinovic R, Patel AR, Lomas DJ, Correa AF, Chen DYT, Rastinehad AR, Schwartz MJ, Uchio EM, Sidana A, Helfand BT, Gahan JC, Yu A, Vourganti S, Barqawi AB, Brisbane WG, Wysock JS, Polascik TJ, McClure TD, Coleman JA. George AK, et al. Cancers (Basel). 2024 Jun 8;16(12):2178. doi: 10.3390/cancers16122178. Cancers (Basel). 2024. PMID: 38927884 Free PMC article.
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).
Geynisman DM, Abbosh PH, Ross E, Zibelman MR, Ghatalia P, Anari F, Mark JR, Stamatakis L, Hoffman-Censits JH, Viterbo R, Greenberg RE, Churilla TM, Horwitz EM, Hallman MA, Smaldone MC, Uzzo R, Chen DYT, Kutikov A, Plimack ER. Geynisman DM, et al. J Clin Oncol. 2025 Mar 20;43(9):1113-1122. doi: 10.1200/JCO-24-01214. Epub 2024 Dec 16. J Clin Oncol. 2025. PMID: 39680823 Clinical Trial.
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.
Hahn NM, O'Donnell MA, Efstathiou JA, Zahurak M, Rosner GL, Smith J, Kates MR, Bivalacqua TJ, Tran PT, Song DY, Baras AS, Matoso A, Choi W, Smith KN, Pardoll DM, Marchionni L, McGuire B, Grace Phelan M, Johnson BA 3rd, O'Neal T, McConkey DJ, Rose TL, Bjurlin M, Lim EA, Drake CG, McKiernan JM, Deutsch I, Anderson CB, Lamm DL, Geynisman DM, Plimack ER, Hallman MA, Horwitz EM, Al-Saleem E, Chen DYT, Greenberg RE, Kutikov A, Guo G, Masterson TA, Adra N, Kaimakliotis HZ. Hahn NM, et al. Eur Urol. 2023 Jun;83(6):486-494. doi: 10.1016/j.eururo.2023.01.017. Epub 2023 Jan 28. Eur Urol. 2023. PMID: 36717286 Free PMC article. Clinical Trial.
Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial.
George AK, Miocinovic R, Patel AR, Lomas DJ, Correa AF, Chen DYT, Rastinehad AR, Schwartz MJ, Sidana A, Stensland KD, Helfand BT, Gahan JC, Meng X, Yu A, Brisbane WG, Vourganti S, Barqawi AB, Uchio EM, Wysock JS, Polascik TJ, McClure TD, Fainberg J, Coleman JA. George AK, et al. Eur Urol. 2025 Jul 19:S0302-2838(25)00346-X. doi: 10.1016/j.eururo.2025.06.003. Online ahead of print. Eur Urol. 2025. PMID: 40685282
Editorial comment.
Chen DY. Chen DY. J Urol. 2009 Nov;182(5):2120-1; discussion 2122. doi: 10.1016/j.juro.2009.07.150. Epub 2009 Sep 16. J Urol. 2009. PMID: 19758612 No abstract available.
Editorial Comment.
Joshi SS, Chen DY. Joshi SS, et al. J Urol. 2017 Feb;197(2):307. doi: 10.1016/j.juro.2016.08.145. Epub 2016 Nov 9. J Urol. 2017. PMID: 27836456 No abstract available.
Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer.
Gore JL, Wolff EM, Comstock BA, Follmer KM, Nash MG, Basu A, Chisolm S, MacLean DB, Lee JR, Lotan Y, Porten SP, Steinberg GD, Chang SS, Gilbert SM, Kessler LG, Smith AB; CISTO Collaborative. Gore JL, et al. BMC Cancer. 2023 Nov 18;23(1):1127. doi: 10.1186/s12885-023-11605-8. BMC Cancer. 2023. PMID: 37980511 Free PMC article.
160 results